Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Novartis reports protein tyrosine kinase inhibitors for bone disorders

Nov. 10, 1997

Cerebrus uses studies on Redux to design new antiobesity agents

Nov. 10, 1997

Profile of Green Cross's rHSA

Nov. 7, 1997

Cell Genesys reports delivery of erythropoietin gene therapy

Nov. 7, 1997

Neuropeptide Y5 receptor emerges as an important new target in obesity

Nov. 6, 1997

NPS and SmithKline Beecham extend osteoporosis agreement

Nov. 5, 1997

Labeling changes for Rezulin; FDA and manufacturer recommend liver function tests

Nov. 5, 1997

Novo Nordisk reports improved human insulin derivatives

Nov. 5, 1997

Phase III safety and efficacy data reported for one-alpha D2

Nov. 4, 1997

Preclinical results with Ergo Science's neuroendocrine resetting therapy

Nov. 4, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 29, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 26, 2026
TROP2 ADCs progress into first-line for lung, breast cancers
BioWorld
Multiple updates on TROP2-directed antibody-drug conjugates (ADCs) for lung and breast cancers highlight both progress made and opportunities for improvement for...
Researchers identify innate immune barrier against melanoma
BioWorld
Australian researchers have identified a previously overlooked population of immune cells in the skin that physically restrain melanoma growth by engulfing live...
Cavalon Therapeutics and Northwestern patent new Cav1.3 blockers
BioWorld Science
Cavalon Therapeutics Inc. and Northwestern University have disclosed new voltage-gated calcium channel Cav1.3 blockers potentially useful for the treatment of...